Related Experiment Videos
Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma
Insights
Blastic natural killer cell leukemia/lymphoma (blastic NKL/L) is a rare cancer. This case study details a patient with blastic NKL/L who achieved long-term remission with acute lymphoblastic leukemia chemotherapy, challenging the typical poor prognosis.
Area of Science:
- Hematology
- Oncology
- Immunophenotyping
Background:
- Blastic natural killer cell leukemia/lymphoma (blastic NKL/L) presents with blastic morphology and a unique immunophenotype, often mimicking acute myeloid or lymphoid leukemia.
- Systematic identification of clinical, pathological, and cytogenetic features of blastic NKL/L remains limited.
- Understanding the specific characteristics of blastic NKL/L is crucial for accurate diagnosis and treatment strategies.
Observation:
- A case of blastic NKL/L is presented with skin lesions, adenopathy, and systemic lymphadenopathy.
- Tumor cells were immunophenotypically characterized as CD4+, CD56+, and negative for T-cell, B-cell, and myeloid markers.
- Bone marrow cells exhibited germ-line configurations for T-cell receptor and immunoglobulin heavy chain genes, and no Epstein-Barr virus infection was detected.
Findings:
- The patient received combined chemotherapy typically used for acute lymphoblastic leukemia.
- Despite the generally poor prognosis and chemotherapy resistance associated with blastic NKL/L, the patient achieved and maintained complete remission for over 13 months.
- Detailed cytogenetic analysis using G-banding and spectral karyotyping revealed a complex karyotype: 45, XY, der(1)t(1;20)(p32;q11.2), der(6)(1pter-->1p32::6p21.1-->6q13::7q11.2-->7qter), der(7)t(7;20)(q11.2;q11.2), t(13;14)(q14;q32), der(13)t(6;13)(p21.1;q14), -20.
Implications:
- This case suggests that blastic NKL/L may be responsive to chemotherapy regimens typically used for acute lymphoblastic leukemia.
- The findings challenge the conventional understanding of blastic NKL/L as universally chemotherapy-resistant with a poor prognosis.
- Further research into novel therapeutic approaches and detailed cytogenetic analysis is warranted for blastic NKL/L management.
Abstract:
Blastic natural killer cell leukemia/lymphoma (blastic NKL/L) is characterized by blastic morphology and a distinctive immunophenotype combining blastic features and cytologically resembling acute myeloid or lymphoid leukemia. The clinical, pathologic, and cytogenetic features of blastic NKL/L have not yet been systematically identified. We report herein a case of blastic NKL/L with skin lesion, adenopathy, and systemic lymphoadenopathy. The identified tumor cells were positive for CD4 and CD56, and negative for T-cell, B-cell, and myeloid markers. T-cell receptor beta, gamma, delta, and immunoglobulin heavy chain genes in the bone marrow cells showed germ-line configurations. Southern blot analysis with a terminal probe did not reveal any Epstein-Barr virus infection. Although patients diagnosed as blastic NKL/L have generally shown chemotherapy resistance and poor prognosis, our patient was treated with a combined chemotherapy, which is also used for acute lymphoblastic leukemia, and has maintained complete remission (CR) for more than 13 months. In addition to clinical investigations, we thoroughly analyzed his karyotype by using a combination of G-banding and a new technique, spectral karyotyping. The karyotype was described as 45, XY, der(1)t(1;20)(p32;q11.2), der(6) (1pter-->1p32:: 6p21.1-->6q13:: 7q11.2-->7qter), der(7) t(7;20)(q11.2;q11.2), t(13;14)(q14;q32), der(13)t(6;13) (p21.1; q14), -20.